Search Videos and More
Dana-Farber Cancer Institute Celebrates 75th Anniversary
Dana-Farber Cancer Institute launched a year-long celebration of its 75th anniversary to highlight its history and progress in cancer care and transformative cancer research. In marking the notable anniversary, Dana-Farber seeks to recognize the Institute’s many scientific discoveries, advancements in cancer care for patients, and its extraordinary contributions to eradicating cancer in both children and adults.Study of Fully Vaccinated Patients with Cancer who had Breakthrough COVID-19 Shows 13% Mortality Rate
The first study to evaluate the clinical characteristics and outcomes of fully vaccinated patients with cancer who had breakthrough COVID-19 infections indicates they remained at high risk for hospitalization and death.COVID-19 and Cancer: Breakthrough Infections
New study: Fully vaccinated patients with cancer who had breakthrough COVID-19 infections remained at high risk for hospitalization and death. Dana-Farber's Toni Choueiri, MD, highlights the research.Study Identifies Factors in Tumors’ Response to Natural Killer Cells
The immune cells known as natural killer (NK) cells are part of the body’s first line of defense against cancer. Many efforts are underway to harness NK cells as a form of cancer immunotherapy, but a critical question in the field remains: Why do some tumors tend to be sensitive to NK cells’ attacks while others are more resistant?Unraveled
Five Dana-Farber Cancer Institute Faculty Members are Inducted in the 2021 Giants of Cancer Care®
Five Dana-Farber Cancer Institute faculty members are inductees of the 2021 Giants of Cancer Care® program.Personalized Cancer Vaccine Helps Patient
Richard Boylan speaks out about his experience with a personalized kidney cancer vaccine, saying he's 'extraordinarily lucky.' He's part of a clinical trial at Dana-Farber Cancer Institute. His doctor, David Braun, MD, PhD, is one of the scientists leading the research.Study Reveals Factor That Determines ‘Fate’ of Cancer Cells When Tumor Suppressor Gene Function is Restored
Many cancers develop from cells that have a malfunctioning tumor suppressor gene, p53, which normally helps control unchecked cell growth and prevent cancer.Cancer Screenings Rebounded in Late 2020 After COVID-related Decline, but Racial and Economic Disparities Remain for Some Tests
The numbers of cancer screening tests rebounded sharply in the last quarter of 2020, following a dramatic decline in the first months of the COVID-19 pandemic, at one large hospital system in the Northeastern United States. These findings were released in a study published in Cancer Cell. The research also found an increase in racial and socioeconomic disparities among users of some screening tests during the pandemic.Expert Panel Issues Recommendations for Addressing Cancer Inequities
New recommendations co-developed by Dana-Farber Cancer Institute call for a significant expansion of the National Cancer Institute (NCI) and NCI-designated Comprehensive Cancer Centers to understand the causes of inequities in cancer care and a commitment to building sustained community partnerships to reduce them.Dana-Farber Research Looks at Blood Test to Detect Cancer
Dana-Farber’s Deborah Schrag, MD, MPH, is leading the Pathfinder Study, a study that looks at a simple blood test and evaluates it to see if it could detect multiple cancer types at the earliest and most treatable stages.